Effect of Rosuvastatin Versus Placebo on Cardiovascular Outcomes in Patients with End-Stage Renal Disease on Hemodialysis – Results of the AURORA Study.
Experience with Antibody-Mediated Rejection Millie Samaniego, M.D. Associate Professor of Medicine University of Wisconsin and Robert A. Montgomery, M.D.,
how_long_do_treatment_effects_last._persistence_and_durability_of_a_descriptive_norms_interventions_effect_on_energy_conservation.pdf
TREATMENT NON-COMPLIANCE IN PSYCHIATRY. NON-COMPLIANCE: PREVALENCE REASONS CLINICAL CONSEQUENCES - Dr. Ashish Srivastava, M.D.
Cost of & Access to Molecularly Targeted Therapies as Barriers to Optimal Care H. Jack West, MD Swedish Cancer Institute Seattle, WA Global Resource for.
PERINATAL MOOD DISORDERS: Update on Psychotropic Prescribing.
Genitourinary Oncology ASCO 2009 Toni K. Choueiri, MD Dana-Farber Cancer Institute Harvard Medical School Boston, Massachusetts U.S.A.
Cost of & Access to Molecularly Targeted Therapies as Barriers to Optimal Care H. Jack West, MD
2 Lucio Crinò Medical Oncology Department University Hospital Perugia, Italy The optimal therapeutic algorithm for EML4-ALK + ve pts.
Bevacizumab plus Interferon-alpha versus Interferon-alpha Monotherapy in Patients with Metastatic Renal Cell Carcinoma: Results of Overall Survival for.
Background
Surgery: Considerations and Research
